Education
About Us
Working with TipRanks
Follow Us
Jeffrey Burbank Insider Profile
4 Followers
Jeffrey Burbank, CEO, Director at NxStage Medical, holds 47.47K shares in Artivion (Ticker: AORT), holds 781.65K shares in NxStage Medical (Ticker: NXTM).
Profitable Transactions
2 out of 3 Profitable Transactions
Average Return
+55.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jeffrey Burbank's holdings
Insider Roles
Director
Roles that Jeffrey Burbank holds in companies
Most Profitable Insider Trade
Stock:
NxStage Medical
(NXTM)
(NXTM)
Rating:Informative Buy
Date:Nov 20, 2013 - Nov 20, 2014
Return:+93.90%
The most profitable trade made by Jeffrey Burbank
Jeffrey Burbank's Trading History
NxStage Medical
Oct 27, 2017
―
Uninformative Sell
―
$23.45M
Artivion
Jun 03, 2024
Director
Uninformative Buy
―
$1.15M
List of latest transactions for each holding click on a transaction to see Jeffrey Burbank's performance on stock
You May Also Like
Jeffrey Burbank insider profile FAQ
What is the percentage of profitable transactions made by Jeffrey Burbank?
The percentage of profitable transactions made by Jeffrey Burbank is 67%.
What is the average return per transaction made by Jeffrey Burbank?
The average return per transaction made by Jeffrey Burbank is 55.60%.
What stocks does Jeffrey Burbank hold?
Jeffrey Burbank holds: NXTM, AORT stocks.
What was Jeffrey Burbank’s latest transaction?
Jeffrey Burbank latest transaction was an Uninformative Buy of ―.
What was Jeffrey Burbank's most profitable transaction?
Jeffrey Burbank’s most profitable transaction was an Informative Buy of NXTM stock on November 20, 2013. The return on the trade was 93.90%.
What is Jeffrey Burbank's role in NxStage Medical?
Jeffrey Burbank's role in NxStage Medical is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.